Compare TRX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | ORMP |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 170.3M |
| IPO Year | 2002 | 2010 |
| Metric | TRX | ORMP |
|---|---|---|
| Price | $1.16 | $5.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 212.4K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $84.84 | N/A |
| Revenue Next Year | $96.90 | N/A |
| P/E Ratio | ★ N/A | $1.85 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $0.37 | $2.09 |
| 52 Week High | $2.80 | $5.47 |
| Indicator | TRX | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 66.78 |
| Support Level | $1.23 | $3.91 |
| Resistance Level | $1.34 | $5.10 |
| Average True Range (ATR) | 0.06 | 0.23 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 92.02 | 70.23 |
TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.